VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells

Oncology Reports

Volumn 17, Issue 6, 2007, Pages 1413-1419

  Cash, Jennifer ^a   Korchnak, Amanda ^a   Gorman, Jacquelyn ^a   Tandon, Yasmeen ^a   Fraizer, Gail ^a  

^a KENT STATE UNIVERSITY   (United States)

Author keywords

Denys Drash syndrome; LNCaP; Prostate cancer cells; Vascular endothelial growth factor; Wilms' tumor gene

Indexed keywords

DACTINOMYCIN; HORMONE; VASCULOTROPIN A; WT1 PROTEIN;

ANGIOGENESIS; ARTICLE; DENYS DRASH SYNDROME; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROSTATE TUMOR; RNA STABILITY; TUMOR CELL LINE; VASCULARIZATION;

CELL LINE, TUMOR; DACTINOMYCIN; DENYS-DRASH SYNDROME; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; MALE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTATIC NEOPLASMS; RNA STABILITY; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WT1 PROTEINS;

EID: 34548050703     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.6.1413     Document Type: Article

References (50)

1. Reddy JL and Licht J: The WT1 Wilms' tumor suppressor gene: how much do we really know? BBA 1287: 1-28, 1996.
2. Mrowka C and Schedl A: Wilms' tumor suppressor gene WT1: From structure to renal pathophysiologic features. J Am Soc Nephrol 11: S106-S115, 2000.
3. Roberts S: Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 15: 542-547, 2005.
4. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R and Fouser L: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys- Drash syndrome. Cell 67: 437-447, 1991. (Pubitemid 121001458)
5. Fraizer GC, Leahy R, Priyadarshini S, Graham K, Delacerada J and Diaz M: Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene. Int J Oncol 24: 461-471, 2004.
6. Graham K, Li W, Williams BRG and Fraizer G: Vascular endothelial growth factor (VEGF) is suppressed in WT1- transfected LNCaP cells. Gene Expr 13: 1-14, 2006.
7. Josko J and Mazurek M: Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10: RA89-RA98, 2004. (Pubitemid 38525095)
8. Ladomery MR, Sommerville J,Woolner S, Slight J and Hastie ND: Expression in Xenopus Oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one. J Cell Sci 116: 1539-1549, 2002. (Pubitemid 36527500)
9. Zhai G, Iskandar M, Barilla K and Romaniuk P: Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1. Biochemistry 40: 2032-2040, 2001. (Pubitemid 32165672)
10. Hanson J, Gorman J, Reese J and Fraizer G: Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci 12: 2279-2290, 2007.
11. Brown TR, Rothwell SW and Migeon CJ: Comparison of methyltrienolone and dihydrotestosterone binding and metabolism in human genital skin fibroblasts. J Steroid Biochem 14: 1013-1022, 1981. (Pubitemid 12217996)
12. Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor, New York, 1989.
13. Simpson D, Feeney S, Boyle C and Stitt A: Retinal VEGF mRNA measured by SYBR Green I fluorescence: A versatile approach to quantitative PCR. Mol Vision 6: 178-183, 2000.
14. Patmasiriwat P, Fraizer G, Kantarjian H and Saunders GF: WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 13: 891-900, 1999. (Pubitemid 29292140)
15. Livak K and Schmittgen TD: Analysis of relative gene expression data using realtime quantitative PCR and the 2-ddCt method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
16. Hanson J, Reese J, Gorman J, Cash J and Fraizer G: Hormone treatment enhances WT1 activation of Renilla luciferase constructs in LNCaP cells. Front Biosci 12: 1387-1394, 2007. (Pubitemid 46846841)
17. Zaia A, Fraizer GC, Piantanelli L and Saunders GF: Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Anticancer Res 21: 1-10, 2001. (Pubitemid 32267618)
18. Shimamura R, Fraizer GC, Trapman J, Lau YC and Saunders GF: The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerianinhibiting substance, and the androgen receptor. Clin Cancer Res 3: 2571-2580, 1997.
19. Shi Q, L. X., Abbruzzese JL, Peng Z, Qian C-N, Tang H, Xiong Q, Wang B, Li X-C and Xie K: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61: 4143-4154, 2001. (Pubitemid 32720983)
20. Sims RJ, Liss AJ and Gottlieb PD: Normalization of luciferase reporter assays under conditions that alter internal controls. Biotechniques 34: 938-940, 2003.
21. Sordello S, Bertrand N and Plouet J: Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251, 1998.
22. Aslan G, Cimen S, Yorukoglu K, Tuna B, Sonmez D, Mungan U and Celebi I: Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract 201: 593-598, 2005. (Pubitemid 41363954)
23. Stewart RJ, Panigrahy D, Flynn E and Folkman J: Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165: 688-693, 2001. (Pubitemid 32060501)
24. Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M and Safe S: Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor a and SP proteins. Oncogene 23: 1052-1063, 2004. (Pubitemid 38269959)
25. Mueller MD, Vigne J-L, Minchenko A, Lebovic DI, Leitman DC and Taylor RN: Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors a and b. Proc Natl Acad Sci USA 97: 10972-10977, 2000.
26. Gao X, Chen X, Taglienti M, Rumballe B, Little M and Kreidberg J: Angioblast-mesenchyme induction of early kidney development is mediated by Wt1 and Vegfa. Development 132: 5437-5449, 2005. (Pubitemid 43125871)
27. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Ziegler U, Gubler MC and Schedl A: Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 106: 319-329, 2001. (Pubitemid 32772616)
28. Kreidberg J, Sariola H, Loring J, Maeda M, Peletier J, Housman D and Jaenisch R: WT1 is required for early kidney development. Cell 74: 679-691, 1993. (Pubitemid 23259748)
29. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND and Bard JBL: The expression of the Wilms' tumor gene, WT1, in the developing mammalian embryo. Mech Develop 40: 85-97, 1992. (Pubitemid 23030564)
30. Karth J, Ferrer F, Perlman E, Hanrahan C, Simons JW, Gearhart JP and Rodriguez R: Coexpression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in Wilms' tumor. J Pediatr Surg 35: 1749-1753, 2000.
31. Baudry D, Faussillon M, Cabanis M, Rigolet M, Zucker J, Patte C, Sarnacki S, Boccon-Gibod L, Junien C and Jeanpierra C: Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour. Oncogene 21: 5566-5573, 2002. (Pubitemid 34983546)
32. Mazzucchelli R, Montironi R, Santinelli A, Lucarinia G, Pugnaloni A and Biagini G: Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45: 72-79, 2000.
33. Dong G, Rajah T, Vu T, Hoffman A, Rosenfeld R, Roberts C, Peehl D and Cohen P: Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 82: 2198-2203, 1997. (Pubitemid 27287584)
34. Dechsukhum C, Ware JL, Ferreira-Gonzalez A, Wilkinson DS and Garrett CT: Detection of a novel truncated WT1 transcript in human neoplasia. Mol Diagn 5: 117-128, 2000.
35. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP and Rauscher F III: Repression of the insulin-like growth factor II gene by the Wilms' tumor suppressor WT1. Science 257: 674-678, 1992.
36. Werner H, Rauscher FJ, Sukhatme VP, Drummond IA, Roberts CT and Leroith D: Transcriptional repression of the insulin-like growth factor I receptor (IGF-IR) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 269: 12577-12582, 1994.
37. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R and Lopez-Berestein G: Par-4 transcriptionally regulates Bcl-2 through WT1-binding site on the Bcl-2 promoter. J Biol Chem 278: 19995-20005, 2003. (Pubitemid 36799192)
38. Hewitt S, Hamada S, McDonnell T, Rauscher F and Saunders GF: Regulation of the Proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res 55: 5386-5389, 1995.
39. Heckman C, Mochon E, Arcinas M and Boxer L: The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas. J Biol Chem 272: 19609-19614, 1997. (Pubitemid 27337765)
40. Morrison DJ, English MA and Licht JD: WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res 15: 8174-8182, 2005. (Pubitemid 41330581)
41. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM and Shi Y: A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16: 6945-6956, 1996. (Pubitemid 26389754)
42. Gashler AL, Bonthron DT, Madden SL, Rauscher FJ, Collins T and Sukhatme VP: Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 89: 10984-10988, 1992.
43. Wang ZY, Madden SL, Deuel TF and Rauscher F III: The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 267: 21999-22002, 1992.
44. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ and Kim S-J: Repression of the transforming growth factor-beta-1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 8: 595-602, 1994. (Pubitemid 24174496)
45. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR and Haber DA: WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 14: 4662-4675, 1995.
46. Tajinda K, Carroll J and Roberts CT Jr: Regulation of insulinlike growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor. Endocrinology 140: 4713-4724, 1999. (Pubitemid 30666139)
47. Caricasole A, Duarte A, Larsson SH, Hastie ND, Little M, Holmes G, Todorov I and Ward A: RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci USA 93: 7562-7566, 1996. (Pubitemid 26277075)
48. Bardeesy N and Pelletier J: Overlapping RNA and DNA binding domains of the WT1 tumor suppressor gene product. Nucleic Acids Res 26: 1784-1792, 1998. (Pubitemid 28291817)
49. Onesto C, Berra E, Grepin R and Pages G: Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J Biol Chem 279: 34217-34226, 2004. (Pubitemid 39318045)
50. Shih S-C and Claffey KP: Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem 274: 1359-1365, 1999.